Wake Forest University School of Medicine Researchers Yield New Data on Psoriasis (Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52).

Předmět:	MEDICAL research SKIN diseases REPORTERS & reporting DRUG therapy MONOCLONAL antibodies
Zdroj:	Immunotherapy Weekly; 12/24/2024, p3290-3290, 1p
Abstrakt:	Researchers from Wake Forest University School of Medicine conducted a study comparing the efficacy, safety, and immunogenicity of biosimilar SB17 to reference ustekinumab (UST) in patients with moderate to severe plaque psoriasis. The study involved switching patients from UST to SB17 and assessing outcomes up to Week 52. Results showed that SB17 demonstrated clinical biosimilarity to UST after switching and maintained comparable efficacy and safety with UST. This research provides valuable insights into the use of biosimilars in treating psoriasis. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu